【摘要】 目的:观察异基因脾细胞经门静脉途径输注诱导受体免疫耐受的效果,以及联合使用塞尼哌后的效果。方法:将供体SD大鼠的脾细胞经门静脉途径输注给受体Wistar大鼠,一周后把SD大鼠的皮肤移植到相应的Wistar大鼠上。移植前联合使用塞尼哌。观察术后移植皮肤的存活时间和受体外周血淋巴细胞CD25+的表达水平。结果:门静脉耐受诱导后移植皮肤的平均存活时间(MST)为(15.8±2.1)d,较对照组长(P<0.01);随移植皮肤存活时间的延长,外周血淋巴细胞的CD25+表达水平呈下降趋势。但使用塞尼哌后MST未延长。结论:经门静脉途径输注异基因脾细胞能够诱导受体产生免疫低应答状态,联合使用塞尼哌未能加强免疫耐受的诱导效果。更多还原

【Abstract】 Objective: To study the effects of immunological tolerance induced by administration of allogeneic splenocytes through portal vein in rats in combination with Daclizumab. Methods: Administration of the splenocytes from the SD rat to the Wistar rat through portal vein .Allogeneic skin transplantation was established a week later. Daclizumab was administrated before the transplantation. The survival time of the grafts was observed and the immunological states of the recipients were evaluated after skin transplantation. Result: The graft mean survival time(MST) in the portal venous tolerance were (15.8±2.1)d, significantly longer than that in the control group(P<0.01);measurement of CD25+ T lymphocytes and T lymphocytes subsets showed lower level of transplantation reaction following administration of the allogeneic splenocytes. But the MST was not prolonged after administration of Daclizumab. Conclusion: Administration of allogeneic splenocytes through portal vein in rat induced immunological tolerance. Combination with Daclizumab can not enhance such tolerance.更多还原